Conference
Phase I study of the LSD1 inhibitor tranylcypromine (TCP) in combination with all-trans retinoic acid (ATRA) and low-dose cytarabine (LDAC) in elderly, medically non-fit patients with AML or high-risk MDS (TRANSATRA trial)
Authors
Kruszewski M; Schmoor C; Berg T; Schittenhelm M; Goetze K; Kuendgen A; Pabst C; Ma T; Frey A; Moschalski K
Volume
46
Pagination
pp. 101-101
Publisher
KARGER
Publication Date
October 3, 2023
Conference proceedings
ONCOLOGY RESEARCH AND TREATMENT
ISSN
2296-5270